Opinion | India’s Ayush industry needs an entirely new regulatory model
This industry has gotten away with light rules for too long and we must insist on tighter standards of therapeutic evidence
The controversy that has erupted over Patanjali’s claim to have developed a cure for covid—called Coronil—has once again cast a spotlight on India’s Ayush industry. In the past, this industry, often supported by government laboratories, has peddled remedies for diabetes, malaria, dengue and rheumatoid arthritis without demonstrating any clinical proof of efficacy that would withstand rigorous scientific scrutiny.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more